U.S. patent application number 11/414003 was filed with the patent office on 2007-01-18 for rapid sterilization system.
Invention is credited to Paul T. Jacobs, Jed Kendall, James P. Kohler, Szu-Min Lin, Robert Lukasik, Jenn-Hann Wang, Harold R. Williams.
Application Number | 20070014691 11/414003 |
Document ID | / |
Family ID | 35187282 |
Filed Date | 2007-01-18 |
United States Patent
Application |
20070014691 |
Kind Code |
A1 |
Lin; Szu-Min ; et
al. |
January 18, 2007 |
Rapid sterilization system
Abstract
A sterilization system includes a sterilization chamber, a
vacuum pump associated with the sterilization chamber, a vaporizer
in association with the sterilization chamber, a sterilant
distillation system associated with the chamber, a source of
sterilant solution associated with the vaporizer and with the
sterilant distillation system, and a control system which has
programmed therein a first cycle in which the sterilant is admitted
to the sterilization chamber at a first concentration, and a second
cycle in which sterilant is concentrated in the sterilant
distillation system to a second concentration, higher than the
first concentration and from there admitted into the sterilization
chamber and wherein the first and second cycles are selectable.
Inventors: |
Lin; Szu-Min; (Irvine,
CA) ; Jacobs; Paul T.; (Bicknell, UT) ; Wang;
Jenn-Hann; (Northridge, CA) ; Kohler; James P.;
(Mission Viejo, CA) ; Kendall; Jed; (San Clemente,
CA) ; Williams; Harold R.; (San Clemente, CA)
; Lukasik; Robert; (Lake Elsinore, CA) |
Correspondence
Address: |
PHILIP S. JOHNSON;JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
35187282 |
Appl. No.: |
11/414003 |
Filed: |
April 28, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11093526 |
Mar 30, 2005 |
|
|
|
11414003 |
Apr 28, 2006 |
|
|
|
10962962 |
Oct 12, 2004 |
|
|
|
11093526 |
Mar 30, 2005 |
|
|
|
10403140 |
Mar 31, 2003 |
|
|
|
10962962 |
Oct 12, 2004 |
|
|
|
09975714 |
Oct 11, 2001 |
|
|
|
10403140 |
Mar 31, 2003 |
|
|
|
09223479 |
Dec 30, 1998 |
6325972 |
|
|
09975714 |
Oct 11, 2001 |
|
|
|
10186019 |
Jun 28, 2002 |
6852279 |
|
|
11093526 |
|
|
|
|
10403450 |
Mar 31, 2003 |
|
|
|
11414003 |
Apr 28, 2006 |
|
|
|
10186019 |
Jun 28, 2002 |
6852279 |
|
|
10403450 |
Mar 31, 2003 |
|
|
|
Current U.S.
Class: |
422/62 ;
422/292 |
Current CPC
Class: |
A61L 2/24 20130101; A61L
2202/122 20130101; A61L 2/208 20130101; A61L 2202/14 20130101 |
Class at
Publication: |
422/062 ;
422/292 |
International
Class: |
A61L 2/24 20070101
A61L002/24; A61L 2/20 20070101 A61L002/20 |
Claims
1. A sterilization system comprising: a sterilization chamber; a
vacuum pump associated with the sterilization chamber; a vaporizer
in association with the sterilization chamber; a sterilant
distillation system associated with the chamber; a source of
sterilant solution associated with the vaporizer and with the
sterilant distillation system; and a control system for controlling
operation of the vacuum pump, vaporizer, and sterilant distillation
system, the control system having programmed therein a first cycle
in which the sterilant is admitted to the sterilization chamber at
a first concentration, and a second cycle in which sterilant is
concentrated in the sterilant distillation system to a second
concentration, higher than the first concentration and from there
admitted into the sterilization chamber and wherein the first and
second cycles are selectable.
2. A sterilization system according to claim 1 wherein the first
and second cycles are selectable by a user.
3. A sterilization system according to claim 1 wherein the first
cycle is adapted to sterilize devices having a first pre-determined
lumen dimensions and the second cycle is adapted to sterilize
devices having a second pre-determined lumen dimensions and wherein
the first cycle is faster than the second cycle and the first
pre-determined lumen dimensions is shorter or larger than the
second pre-determined lumen dimensions.
4. A sterilization system according to claim 1 and further
comprising a valve to separate the vaporizer from the sterilization
chamber.
5. A sterilization system according to claim 4 wherein the first
cycle is configured to vaporize the sterilant with the valve in an
open position.
6. A sterilization system according to claim 4 wherein the second
cycle is configured to vaporize the sterilant with the valve in a
closed position while concentrating the sterilant from the first
concentration to the second concentration.
7. A sterilization system according to claim 6 wherein the second
cycle is configured so that the valve is then opened after the
sterilant concentration is reached to the second concentration.
8. A sterilization system according to claim 4 and further
comprising an orifice between the vaporizer and the sterilization
chamber.
9. A sterilization system according to claim 8 wherein the orifice
is formed through a portion of the valve.
10. A sterilization system according to claim 8 wherein the orifice
is a separate element and is in a parallel position to the
valve.
11. A sterilization system according to claim 1 and further
comprising a condenser between the vaporizer and the sterilization
chamber.
12. A sterilization system according to claim 11 and further
comprising a temperature control system to control the temperature
of condenser.
13. A system according to claim 12 wherein the first cycle is
configured to vaporize the sterilant with the condenser controlled
at a first temperature, wherein the first temperature is higher
then the condensation temperature of the sterilant.
14. A system according to claim 12 wherein the second cycle is
configured to vaporize the sterilant with the condenser controlled
at a second temperature, wherein the second temperature is lower
then the condensation temperature of the sterilant.
15. A system according to claim 14 wherein the second cycle is
configured to set the condenser temperature to a third temperature,
wherein the third temperature is higher then the condensation
temperature of the sterilant.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 11/093,526 filed Mar. 30, 2005 which is a continuation-in-part
of U.S. application Ser. No. 10/962,962 filed Oct. 12, 2004
(attorney docket no. ASP-5022) and which is also a
continuation-in-part of U.S. application Ser. No. 10/403,140 which
is a continuation-in-part of U.S. application Ser. No. 09/975,714
filed Oct. 11, 2001 which is continuation of U.S. application Ser.
No. 09/223,479 filed Dec. 30, 1998, now U.S. Pat. No. 6,325,972;
and which is also a continuation-in-part of U.S. application Ser.
No. 10/186,019 filed Jun. 28, 2002, now U.S. Pat. No. 6,852,279.
This application is also a continuation-in-part of U.S. application
Ser. No. 10/403,450 filed Mar. 31, 2003 which is a
continuation-in-part of U.S. application Ser. No. 10/186,019 filed
Jun. 28, 2002, now U.S. Pat. No. 6,852,279. All of these
applications are hereby incorporated by reference in their
entirety.
FIELD OF THE INVENTION
[0002] The invention relates to sterilization of articles, and more
particularly to sterilization of articles with hydrogen peroxide
vapor.
BACKGROUND OF THE INVENTION
[0003] It is known to sterilize articles with a vaporized chemical
sterilant, such as hydrogen peroxide, peracetic acid and
glutaraldehyde. Wu et al. U.S. Pat. No. 6,365,102, incorporated
herein by reference, describes a hydrogen peroxide/gas plasma
sterilization system comprising a vacuum chamber, source of
hydrogen peroxide vapor and a source of RF energy to create a
plasma. Such systems marketed under the name STERRAD.RTM. are
available from Advanced Sterilization Products division of Ethicon,
Inc. in Irvine, Calif.
[0004] Jacobs et al., U.S. Pat. No. 6,325,972 found that when the
water has a higher vapor pressure than the sterilant component of
the solution, such a solution of hydrogen peroxide, that by
controlling the temperature and pressure at which the solution is
vaporized the water can be preferentially drawn off from the
solution to increase the concentration of the sterilant in the
solution. If the water is exhausted from the system during this
process it leaves a higher concentration of the sterilant in the
system. The higher concentration of sterilant during the phase in
which the vapor phase sterilant contacts articles to be sterilized
leads to increased efficiency in the sterilization process.
[0005] Jacobs et al. (US Application Publication No. US
2003/0235511 published Dec. 25, 2003) also explored the
efficiencies gained by preferentially condensing the sterilant to
enhance the concentration process.
[0006] The present invention further improves upon Jacobs et al.
'511 by improving the speed at which sterilization can be
completed, especially the sterilization of articles having
lumens.
SUMMARY OF THE INVENTION
[0007] A sterilization system according to the present invention
comprises a sterilization chamber, a vacuum pump associated with
the sterilization chamber, a vaporizer in association with the
sterilization chamber, a sterilant distillation system associated
with the chamber, a source of sterilant solution associated with
the vaporizer and with the sterilant distillation system, and a
control system for controlling operation of the vacuum pump,
vaporizer, and sterilant distillation system, the control system
having programmed therein a first cycle in which the sterilant is
admitted to the sterilization chamber at a first concentration, and
a second cycle in which sterilant is concentrated in the sterilant
distillation system to a second concentration, higher than the
first concentration and from there admitted into the sterilization
chamber and wherein the first and second cycles are selectable.
[0008] Preferably, the first and second cycles are selectable by a
user, although other options could be employed such as having the
cycles selected by the control system based upon information about
a device to be sterilized. That information might include lumen
lengths, diameters and materials, either entered directly or looked
up via model or tag number information.
[0009] Preferably, the first cycle is adapted to sterilize devices
having a first pre-determined lumen dimensions and the second cycle
is adapted to sterilize devices having a second pre-determined
lumen dimensions and wherein the first cycle is faster than the
second cycle and the first pre-determined lumen dimensions is
shorter or larger than the second pre-determined lumen
dimensions.
[0010] In one aspect of the invention, a valve separates the
vaporizer from the sterilization chamber. Preferably, the first
cycle is configured to vaporize the sterilant with the valve in an
open position. Preferably, the second cycle is configured to
vaporize the sterilant with the valve in a closed position while
concentrating the sterilant from the first concentration to the
second concentration. The second cycle can be configured so that
the valve is then opened after the sterilant concentration is
reached to the second concentration.
[0011] Preferably an orifice is located between the vaporizer and
the sterilization chamber. Preferably, the orifice is formed
through a portion of the valve. It can also be a separate element
and which is in a parallel position to the valve.
[0012] Preferably, a condenser is employed between the vaporizer
and the sterilization chamber so as to further concentrate the
sterilant solution by selectively condensing sterilant out of vapor
phase sterilant solution. Preferably, a temperature control system
controls the temperature of condenser. Preferably, the first cycle
is configured to vaporize the sterilant with the condenser
controlled at a first temperature, wherein the first temperature is
higher then the condensation temperature of the sterilant.
Preferably, the second cycle is configured to vaporize the
sterilant with the condenser controlled at a second temperature,
wherein the second temperature is lower then the condensation
temperature of the sterilant. Preferably, the second cycle is
configured to then set the condenser temperature to a third
temperature, wherein the third temperature is higher then the
condensation temperature of the sterilant.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a block diagram of a sterilization system
according to the present invention;
[0014] FIG. 2 is a block diagram of a vaporizer and diffusion path
of the sterilization system of FIG. 1;
[0015] FIG. 3 is a block diagram of an alternate embodiment of a
sterilization system according to the present invention;
[0016] FIG. 3A is a block diagram of an alternative embodiment of a
sterilization system according to the present invention.
[0017] FIG. 3B is a sectional view taken along lines 3B-3B of FIG.
3A;
[0018] FIG. 4 is a block diagram of an alternate embodiment of a
sterilization system according to the present invention;
[0019] FIG. 5 is a block diagram of an alternate embodiment of a
sterilization system according to the present invention;
[0020] FIG. 6 is a section view taken along lines 6-6 of FIG.
5;
[0021] FIG. 7 is a block diagram of an alternate embodiment of a
sterilization system according to the present invention;
[0022] FIG. 8 is a section view taken along lines 8-8 of FIG.
7;
[0023] FIG. 9 is a block diagram of a sterilization system
according to the present invention;
[0024] FIG. 10 is a cut-away view of an outlet condenser/vaporizer
for use in the system of FIG. 9;
[0025] FIG. 11 is a cut-away view of an inlet condenser/vaporizer
for use in the system of FIG. 9;
[0026] FIG. 12 is a perspective view of an alternative inlet
condenser/vaporizer for use in the system of FIG. 9;
[0027] FIG. 13 is an exploded perspective view of the
condenser/vaporizer of FIG. 12;
[0028] FIG. 14 is a section view taken along lines 14-14 of FIG.
12;
[0029] FIG. 14A is a close-up section view of the valve assembly
shown in FIG. 14;
[0030] FIG. 15 is an exploded perspective view of a thermoelectric
heat pump and rod assembly employed in the condenser/vaporizer of
FIG. 12;
[0031] FIG. 16 is an alternative sterilization system according to
the present invention;
[0032] FIG. 17 is an alternative sterilization system according to
the present invention;
[0033] FIG. 18 is an alternative sterilization system according to
the present invention;
[0034] FIG. 19 is an alternative sterilization system according to
the present invention;
[0035] FIG. 20 is a perspective view of an alternative inlet
condenser/vaporizer for use in the system of FIG. 9;
[0036] FIG. 21 is a valve block employed in the inlet
condenser/vaporizer of FIG. 20; and
[0037] FIG. 22 is a cut-away view of the valve block of FIG. 21 as
employed in the inlet condenser/vaporizer of FIG. 20.
DETAILED DESCRIPTION
[0038] FIG. 1 shows in block diagram form a sterilization system 10
comprising a sterilization chamber 12, a vaporizer 14, and a vacuum
pump 16. The vacuum pump is capable of drawing a vacuum on the
chamber, preferably as low as 0.5 torr. Between the vacuum pump 16
and the chamber 12, is preferably located at throttle valve 18 and
optionally an orifice plate 20. The throttle valve 18 preferably
also has good shut-off capability. A pressure gauge 22, preferably
located adjacent to the throttle valve 18, shows the vacuum in the
chamber 12. A vent valve 23 employing a HEPA antimicrobial filter
allows clean sterile air to enter the chamber 12. The vaporizer 14
connects to the chamber 12 by means of an elongated diffusion path
24. Turning also to FIG. 2, the diffusion path 24 incorporates
temperature control elements 26 to control the temperature along
the diffusion path 24.
[0039] Vaporizers suitable for vaporizing a liquid sterilant such
as hydrogen peroxide solution are known in the art. Kohler et al.
U.S. Pat. No. 6,106,772 and Nguyen et al. U.S. patent application
Ser. No. 09/728,973 filed Dec. 10, 2000, both incorporated herein
by reference, illustrate vaporizers suitable for the present
application. In its simplest for the vaporizer can comprise a small
chamber into which the liquid hydrogen peroxide solution is
injected. The low pressure in the vaporizer caused by the vacuum in
the chamber causes the hydrogen peroxide solution to vaporize.
[0040] Preferably, the vaporizer 14 itself incorporates heating
elements 28 which control the temperature in the vaporizer to
optimize the vaporization process. Preferably, where the vaporizer
14 connects to the diffusion path 24 some form of thermal
insulation 30 provided at the interface so that the high
temperatures of the vaporizer 14 will not unduly affect the
temperature in the diffusion path 24. The vaporizer 14 and
diffusion path 24 are preferably formed of aluminum; the thermal
insulation 30 can take the form of a polyvinyl chloride (PVC) joint
connecting the two together.
[0041] Further, it is preferable to include a heater 32 inside the
chamber 12, preferably near a lower portion of the chamber 12 for
revaporizing condensed hydrogen peroxide inside the chamber 12.
[0042] The chamber 12 preferably includes a mechanism (not shown)
to create a plasma therein. Such mechanism can include a source of
radio or low frequency energy as described by Jacobs et al. U.S.
Pat. No. 4,643,867, or by Platt, Jr. et al. in published U.S.
Application Document No. 20020068012, both of which are
incorporated herein by reference.
[0043] The present invention achieves its beneficial effect by
allowing some of the hydrogen peroxide which is vaporized out of
solution in the vaporizer 14 to condense onto the diffusion path
24. After most of the hydrogen peroxide solution has vaporized, the
temperature control elements 26 raise the temperature of the
diffusion path to allow the condensed hydrogen peroxide to
re-vaporize. Water has a higher vapor pressure than hydrogen
peroxide, thus hydrogen peroxide in the vapor condenses more easily
than water. Thus, the material which condenses in the diffusion
path will have a higher concentration of hydrogen peroxide than the
starting concentration of the hydrogen peroxide solution in the
vaporizer 14.
[0044] The temperature control elements 26 in simple form can
comprise mere electric resistance heaters. In such case, the low
ambient temperature of the diffusion path 24 provides the low
temperature for condensing hydrogen peroxide thereon, and the
control elements 26 later heat the diffusion path 24 to re-vaporize
the now more highly concentrated hydrogen peroxide from the
diffusion path 24. Because the vapor pressure of hydrogen peroxide
drops with lower temperatures, lower initial temperatures in the
diffusion path 24 allows a lower pressure in the chamber 24 without
subsequently preventing the condensation of hydrogen peroxide in
the diffusion path. Lower chamber pressures promote system
efficiency and thus, the temperature control elements 26 can
further comprise a chilling component to lower the temperature of
the diffusion path below ambient. Suitable chilling components
include thermoelectric coolers or a typical mechanical
refrigeration system. In such case, the diffusion path 24 would be
first chilled, preferably to about 10.degree. C., and then some
time after vaporization has begun or even after it has completed,
the diffusion path 24 is then heated, preferably up to 50.degree.
C. or 110.degree. C.
[0045] When vertically oriented as in FIG. 2, the diffusion path 24
can potentially cause the vaporizing sterilant to condense in
cooler regions between the temperature control elements 26 and then
re-vaporize as it passes the temperature control element 26.
[0046] The following example illustrates the benefits of
controlling the heat in the diffusion path.
EXAMPLE 1
[0047] The efficacy tests were conducted by placing a CSR-wrapped
tray (3.5''.times.10''.times.20'') consisting of representative
medical devices and test lumens in a 20-liter aluminum chamber
(4.4''.times.12''.times.22''). A one-inch stainless steel wire
inoculated with at least 1.times.10.sup.6 Bacillus
stearothermophilus spores was placed in the center of each of the
test lumens. The effects with and without temperature control of
the diffusion path were investigated with both a TEFLON,
poly(tetrafluoroethylene)lumen having an internal diameter of 1 mm
and a length of 700 mm, and a stainless steel lumen having an
internal diameter of 1 mm, and a length of 500 mm. All lumens were
open at both ends. Each of the samples were subjected to a
sterilization cycle in a 20 liter vacuum chamber, which was held at
40.degree. C. and 3 torr for 5 minutes. 1.44 ml of a 59% solution
of hydrogen peroxide in water was injected at atmospheric pressure
into the vaporizer which was held at 60.degree. C. The 5 minute
clock then started and the chamber was pumped down to 3 torr, which
took less than one minute. In one case the diffusion path 24 had an
initial temperature of 30.degree. C. for the first minute while the
chamber was evacuated to 3 torr and was then heated to 50.degree.
C. to release the condensed peroxide from the diffusion path into
the chamber for the remainder of the cycle while pressure was
maintained at 3 torr. In the other case, the diffusion path was
held at 50.degree. C. throughout the cycle. By maintaining the
diffusion path at 50.degree. C., no or little peroxide was retained
in the diffusion path. Sterilization effectiveness was measured by
incubating the test samples in growth media at 55.degree. C. and
checking for growth of the test organism. Table 1 shows the results
of these tests. TABLE-US-00001 TABLE 1 30.degree. C. 50.degree. C.
Diffusion Diffusion Path For One Path Minute Then Throughout
increased to Lumen Type ID & Length Process 50.degree. C.
Teflon 1 .times. 700 2/2 0/3 Stainless Steel 1 .times. 500 1/2
0/3
[0048] When the diffusion path temperature was maintained at high
temperature throughout the process, all of the samples in the
TEFLON lumen tested positive for bacteria growth, indicating
failure of sterilization, and one of two samples in the stainless
steel lumen tested positive. Under the same conditions, but with an
initially lower temperature diffusion path which was heated
starting one minute after the diffusion began, none of the samples
tested positive. Condensing the peroxide in the diffusion path
during the initial vaporization stage and then re-vaporizing the
condensed peroxide from the diffusion path into the chamber greatly
enhance the efficacy.
[0049] Additional efficiencies can be achieved by alternating cool
and warm regions in the diffusion path 24 as primarily illustrated
in FIG. 2. The temperature control elements 26, in simple form
heating elements, are spaced apart from one another. Also,
preferably, the diffusion path 24 is vertical in this respect. As
the hydrogen peroxide solution vaporizes and passes through the
diffusion path 24, it is thought that it may alternately condense
and re-vaporize as it passes over the heated and unheated sections
of the diffusion path 24. The diffusion path could alternatively
comprise alternating heating and cooling elements.
[0050] The heater 32 within the chamber 12 acts similarly to the
heating of the diffusion path 24. By controlling the heater 32
temperature, the peroxide can be first condensed on the heater 32
and then re-vaporized into the chamber 12 to concentrate the
peroxide.
[0051] A preferred cycle would be a modification of a cycle
described in the Wu et al. U.S. Pat. No. 6,365,102, incorporated
herein by reference. A series of pre-plasma energy additions with
venting in-between dries moisture from the chamber 12. A vacuum is
then drawn upon the chamber 12 and the hydrogen peroxide solution
injected into the vaporizer 14. Alternatively, the peroxide
solution can also be injected at atmospheric pressure. Some of the
vaporizing solution condenses upon the cool diffusion path 24.
After a time sufficient for most or all of the hydrogen peroxide
solution to vaporize from the vaporizer 14, the diffusion path 24
is warmed by the temperature control elements 26 and the condensed
hydrogen peroxide solution re-vaporizes. At about this time, the
throttle valve 18 is closed and the pump 16 turned off to seal the
chamber 12. Much of the water fraction of the hydrogen peroxide
solution has thus been drawn out of the chamber 12 by the vacuum
pump 16 and the remaining hydrogen peroxide solution which
re-vaporizes from the diffusion path 24, or from the heater 32 in
the chamber 12 if present, is of a higher hydrogen peroxide
concentration than the starting solution. Preferably, a computer
based control system (not shown) controls the functions of the
process for ease and repeatability.
[0052] The hydrogen peroxide vapor thus produced contacts an
article 34 or articles 34 in the chamber 12 and effects
sterilization thereof. If those articles 34 have diffusion
restricted areas, such as long, narrow lumens, it may be preferable
to then vent the chamber 12 and allow clean sterile air therein to
drive the hydrogen peroxide vapor deeper into the diffusion
restricted areas. Then the chamber 12 is again subjected to vacuum
and an additional injection of hydrogen peroxide, preferably with
the heating sequence on the diffusion path, is repeated. After a
time period sufficient to effect sterilization of the article 34,
preferably with a six-log reduction in challenge organisms such as
Bacillus stearothermophilus, a plasma is lit within the chamber 12,
thereby enhancing the sterilization and breaking down the hydrogen
peroxide into water and oxygen.
[0053] The orifice plate 20 can enhance the effect of concentrating
the hydrogen peroxide during its vaporization. As described in the
Lin et al. U.S. Pat. No. 5,851,485, incorporated herein by
reference, a controlled or slow pump-down of the chamber 12
initially draws off more water than hydrogen peroxide from solution
as the water has a higher vapor pressure, thereby leaving a higher
concentration hydrogen peroxide behind. Controlling the pump-down
can be difficult as vacuum pumps generally do not throttle back
well and throttle valves in such service are difficult to control
and expensive. By placing the orifice plate 20 in the flow path to
the pump 16, the amount of atmosphere from the chamber 12 exhausted
by the pump 16 is limited, and by selecting a proper size orifice
36 in the plate 20 can be controlled to a rate which effectively
concentrates hydrogen peroxide in the chamber 12.
[0054] Turning also to FIG. 3, a system 10a, similar in most
respects to the system 10 of FIGS. 1 and 2, with like part numbers
denoted with an "a" appended thereto, also incorporates an orifice
plate 20a. However, to allow a quick pump-down of the chamber 12a,
yet retain the controlled pump-down benefits of the orifice plate
20a, it incorporates two path ways from the pump 16a to the chamber
12a. A first pathway 40 contains a throttle valve 42 and a second
pathway 44 contains a throttle valve 46 and the orifice plate 20a.
Thus, during initial pump-down the first throttle valve 42 is open
leaving the pump 16a freely connected to the chamber 12a. As the
chamber 12a approaches the vapor pressure of water, the first
throttle valve 42 is closed thereby forcing the pump 16a to
evacuate through the orifice plate 20a and thus draw out of the
chamber 12a at a slower, controlled rate more conducive to
preferentially drawing water out of the hydrogen peroxide solution
and out of the chamber 12a.
[0055] Turning also to FIGS. 3A and 3B, a system 110 similar to
that of FIG. 1 is shown. Here, rather than use two paths as in the
system 10a of FIG. 3, a valve 112 comprises a valve body 114, a
valve seat 116 and a valve element 118, such as a butterfly disc,
plug or the like. An orifice 120 is provided through the valve
element. Thus, when the valve 112 is open evacuation can occur
quickly, and when the valve 112 is closed it can occur more slowly.
Such a valve could also be employed between the vaporizer 14 and
the chamber 12 to further control the preferential vaporization and
removal of the water from the germicide solution.
[0056] Turning now to FIG. 4, while highly concentration of the
sterilizing vapor is helpful in achieving sterilization efficiency
and efficacy, getting the vapor into contact with the items to be
sterilized is also a concern. Typically, the low pressures (0.5
torr to 10.0 torr) inside of a chamber 12 promotes quick diffusion
of the sterilant vapor to all areas therein.
[0057] FIG. 4 illustrates a sterilization system 60 comprising a
chamber 62 having a vaporizer 64, vacuum pump 66 and vent 68
connected thereto. Preferably, an elongated, temperature controlled
diffusion path 70 as previously described connects the vaporizer 64
to the chamber 62. A throttle valve 72 and pressure gauge 74 are
provided at the pump 66.
[0058] Articles 76 to be sterilized are placed into trays or
containers 78. Two types of packaging are commonly used in
preparing articles 76 for sterilization. In one, the articles 76
are placed into a tray having a plurality of openings therein, and
the tray is then wrapped with a material such as CSR wrap which
passes sterilizing gases and blocks contaminating microorganisms.
Such a tray is described in the Wu, U.S. Pat. No. 6,379,631,
incorporated herein by reference. An alternative package comprises
a sealable container with several ports, preferably on top and
bottom surfaces thereof, with each of the ports covered by a
semi-permeable membrane which passes sterilizing gases and blocks
admission of contaminating microorganisms. Such a container is
described in Nichols U.S. Pat. No. 4,704,254, incorporated herein
by reference. The first type of packaging is typically called a
"tray" and the second a "container." However, the term "container"
as used herein is meant to refer to any container, packaging or
enclosure suitable for containing articles to be sterilized in a
chemical vapor environment.
[0059] The pump 66 connects to the chamber 62 via an exhaust
manifold 80. The manifold 80 comprises one or more shelves 82 for
supporting and receiving one or more containers 78 and which
connect fluidly through the throttle valve 72 to the pump 66. An
opening, or preferably a plurality of openings 84 on the upper
surfaces of the shelves 82 allow the pump 66 to draw atmosphere
within the chamber 62 through the openings 84, through the manifold
80 and out through the pump 66.
[0060] The containers 78 preferably have openings 86 on a lower
surface 88 thereon and additional openings 90 on at least one other
surface. When the containers 78 are placed on the shelves 82
atmosphere being exhausted by the pump 66 is drawn in part through
the openings 90 into the container 78, through the container into
contact with the article or articles 76 therein and then out
through the openings 86 into the manifold 80 through the openings
84 therein. When the atmosphere being so exhausted contains a
sterilizing gas it enhances its penetration into the containers 78
and into contact with the articles 76 therein.
[0061] Sterilizing gases are so exhausted during the previously
described cycle as the sterilant solution is vaporizing and
immediately before the second admission of hydrogen peroxide. Such
a cycle can also further provide a pump-down after some period of
diffusion. After admitting the sterilant vapor the chamber 62
pressure rises slightly due to the presence of additional gas
therein, typically from about 0.5 torr to about 10 torr. Higher
pressures are as efficient with higher load and chamber
temperatures.
[0062] Turning also to FIGS. 5 and 6, an alternative design (in
which like part numbers to those of the design of FIG. 4 are
designated with a "b" appended thereto) replaces the manifold 80 of
the design of FIG. 4 with a simple port 92. The port 92 is covered
by a support 94 for the container 78, the support 94 having a
plurality of openings 96 therethrough so that the chamber 62b is in
fluid communication with the pump 66b through the container 78, the
support 94 and the port 92. The support 94 can be removable.
[0063] Turning also to FIGS. 7 and 8 (in which like part numbers to
those of the designs of FIGS. 4 to 6 are designated with a "c"
appended thereto) shows a support 100 resting on a surface 102 in
the chamber 62c through which penetrates the port 92c. The support
100 surrounds the port 92c. Thus, most or all of the atmosphere
being exhausted by the pump 66c passes through the container 78
into a space 104 formed between the container 78, the support 100
and the surface 102 and then onto the pump 66c through the port
92c.
[0064] FIG. 9 discloses an alternative system in which, similar to
the system of FIG. 1, a portion of the vaporized germicide solution
can be condensed and the solvent, typically water, which has not
condensed as quickly is removed from the atmosphere to further
concentrate the germicide. The germicide is then revaporized to
produce a more concentrated germicidal vapor for more efficient
sterilization. The system comprises a sterilization chamber 200
containing a load 202 of items to be sterilized. A source 204 of
liquid germicide solution provides the solution through a valve 206
to a first vaporizer/condenser 208 where it is vaporized and then
supplied to the chamber 200. A valve 210 can be provided to isolate
the vaporizer/condenser 208 from the chamber 200. The chamber 200
is also provided with a valved vent 212.
[0065] A vacuum pump 214 provides for lowering the chamber pressure
as described in reference to the previous embodiments. Between the
pump 214 and the chamber 200 a second vaporizer/condenser 216 is
provided for condensing the vaporized solution. Preferably valves
218 and 220 isolate the second vaporizer/condenser 216 from the
pump 214 and chamber 200 respectively.
[0066] Turning also to FIG. 10 a simple version of the second
vaporizer/condenser 216 preferably comprises walls 222 defining an
enclosure 224 having an inlet 226 connected to the chamber 200 and
an outlet 228 connected to the pump 214. A plurality of baffles 230
provides a torturous flow path 232 through the vaporizer/condenser
216. The walls 222, and potentially the baffles 230, are
temperature controllable to enhance condensation of and
re-vaporazation of the solution.
[0067] A similar structure with an inlet can be employed on the
first vaporizer/condenser 208 as well. Turning also to FIG. 11, a
simple version of the first condenser/vaporizer 208 is illustrated.
It comprises an enclosure 240 having an inlet 242 connected to the
source of solution 204 (not shown in FIG. 11) and an outlet 244
connected to the chamber 200 (not shown in FIG. 11). A plurality of
baffles 246 provides a tortuous flow path through the first
vaporizer/condenser 208. The enclosure 240 and potentially the
baffles 246 are temperature controllable to enhance condensation
and revaporization of the solution.
[0068] In a simple cycle, a liquid germicide solution, such as
hydrogen peroxide and water is admitted into the first
vaporizer/condenser 208 where it is vaporized and then flows into
the chamber 200 which is at a low pressure, all as described in
reference to previous embodiments herein. During vaporization and
for sometime thereafter pump 214 continues to exhaust atmosphere
from the chamber 200. By controlling temperature and pressure this
preferentially vaporizes water from the solution over the hydrogen
peroxide and the water vapor is extracted from the system via the
pump 214 to concentrate the hydrogen peroxide solution during the
vaporization phase. Additionally, hydrogen peroxide, having the
lower vapor pressure, will tend to condense more quickly than the
water vapor in the first vaporizer/condenser 208. As the pump 214
continues to exhaust atmosphere from the chamber 200 the vaporized
hydrogen peroxide solution flows out of the chamber and into the
second vaporizer/condenser 216 where a portion thereof will
condense. Due to the preferential condensation of hydrogen peroxide
over the water more of the water vapor will pass through the
condenser 216 uncondensed and be exhausted via the pump 214 thus
allowing further concentration of the hydrogen peroxide solution.
At some point, the pump is turned off and the valve 218 closed. The
condensed hydrogen peroxide within the vaporizer/condenser 216 is
then re-vaporized preferably by heating the condenser 216. This
hydrogen peroxide will have a higher concentration for more
efficient sterilization of the load 202.
[0069] Turning also to FIGS. 12 through 15, a more elaborate
condenser/vaporizer 250 is illustrated. In gross, it comprises an
inlet manifold 252 which connects to the source of sterliant
solution 204 and which provides initial vaporization, a
condensing/revaporization section 254, an outlet manifold 256 and a
control valve 258 via which the vaporizer/condenser 250 connects to
the chamber 200. A resistance heater 260 affixes to the inlet
manifold 252 and to the outlet manifold 256 to provide heat to
assist in the initial vaporization within the inlet manifold 252
and to prevent condensation in the outlet manifold 256. Preferably,
the inlet manifold 252 and outlet manifold 256 are formed of
aluminum. Further, an insulator 262 is provided between the inlet
manifold 252 and the vaporizer/revaporizer section 254.
[0070] The vaporizer/revaporizer section 254 comprises a housing
264, preferably formed of aluminum, open on a first side 266 and
second side 268. A first thermo-electric device 270 and second
thermo-electric device 272 affix to the first side 266 and second
side 268, respectively. The thermoelectric devices 270 and 272
preferably operate under the Peltier effect, although other classes
of thermoelectric devices could be substituted therefor. More
conventional heat pumps, such as freon or ammonia based systems can
also be employed with somewhat greater complexity.
[0071] A first rod assembly 274, comprising a plate 276 and a
plurality of rods 278 extending normally therefrom affixes to the
first thermo-electric device 270 with the rods 278 extending
laterally into the housing 264. A second rod assembly 280 similarly
attaches to the second thermo-electric device 272 with its rods 278
extending laterally into the housing 264 in facing relationship to
the first rod assembly 274. The rod assemblies 274 and 280 are
preferably formed of aluminum.
[0072] Preferably, the rods 278 extend almost to, without touching,
the opposing plate 276. Also, the rods 278 from the two rod
assemblies 274 and 280 lie in a generally parallel relationship
with each other with a spacing therebetween designed to, along with
the volume within the vaporizer/revaporizer section 254, provide a
preferred flow rate of the vaporized sterliant therethrough to
provide efficient condensation on to the rods 278. Preferably, a
flow rate is in the range of 0.1 ft/sec to 5 ft/sec, and more
preferably a flow rate of 0.24 ft/sec is provided.
[0073] In a small condenser with a vapor path length of 3 inches,
the residence time would be 1 second at a preferred velocity of
0.24 ft/sec. This residence time would be sufficient for the
vaporized sterilant to interact with the cooler condenser surfaces
and to condense. For a typical injection volume of 2 ml of
sterilant solution, the surface area of the
condensing/revaporization section 254 would be about 90 square
inches to permit mass transfer for condensation. High temperature
at low pressure in the initial vaporizer (inlet manifold 252)
maintains the water and hydrogen peroxide in the vapor phase for
delivery to the condensing/revaporization section 254. For example,
a vaporizer temperature of 70 degrees C. or greater at a pressure
of 125 torr or lower ensures that a 59 wt % solution of hydrogen
peroxide and water will be in the vapor phase.
[0074] As vapor enters the condensing/revaporization section 254,
which has a lower temperature, the hydrogen peroxide condenses on
the cooler surface forming a concentrated solution. The temperature
and pressure therein determine the concentration of the condensed
solution. For example, at 50 degrees C. and 13 torr in the
condensing/revaporization section 254, the condensed hydrogen
peroxide concentration would be 94 wt %. At 30 degrees C. and 3.8
torr, the condensed hydrogen peroxide concentration also would be
94 wt %. As the pressure in the condensing/revaporization section
254 is lowered, the temperature must also be lowered to maintain
the same concentration of solution.
[0075] The orifice 308 offers the advantage of a more concentrated
solution by restricting the flow from the condensing/revaporization
section 254 to provide a more controlled vaporization. Variations
in pressure in the condensing/revaporization section 254 and in the
vaporizer due to vacuum pump pressure fluctuations are dampened out
by the orifice 308 to prevent surges of water vapor from carrying
hydrogen peroxide droplets from the condensing/revaporization
section 254. Another advantage of flow restriction by the orifice
308 is achieving a low pressure (less than 1 torr) in the
sterilization chamber 200 to improve the diffusion coefficient in
lumens while maintaining a greater pressure in the
vaporizer/condenser 250 to operate at a greater temperature in the
condensing/revaporization section 254. Without an orifice 308,
sterilization chamber 200 and vaporizer/condenser 250 pressures
must both be reduced to the same low pressure together, and the
condenser must be operated at a very low temperature to maintain
equilibrium of the solution. A lower condenser temperature is more
difficult to control and may produce ice or condensate, which
requires a more expensive design to protect electrical
equipment.
[0076] An O-ring 282 seals the plates 276 on the thermo-electric
devices 270 and 272 against the housing 264. An aperture 284
through the housing 264 aligns with an aperture 286 through the
insulator 262 to place a chamber 288 defined by the housing 264
into fluid communication with the inlet manifold 252. An outlet
passage 290 in the housing 264 connects to an upper portion of the
chamber 288 and to a second aperture 292 through the insulator 262
which in turn aligns with the outlet manifold 256 to place the
chamber 288 in fluid communication with the outlet manifold 256. A
safety thermostat 294 atop the housing 264 is wired outside of the
control system to shut down heating of the vaporizer/condenser 250
above a predetermined temperature. Temperature sensors 295 and 297
measure temperature in the inlet manifold 252 and
condensing/revaporization section 254 respectively. A pressure
sensor 296 interfaces with the outlet manifold 256. Heat sinks 298
having fan housings attach to each of the thermo-electric devices
270 and 272.
[0077] The outlet manifold connects to a valve manifold 300 which
provides three possible flow paths between the vaporizer/condenser
250 outlet manifold 256 and a valve manifold outlet 302 from the
valve manifold 300. The valve manifold outlet 302 communicates with
the main chamber 200. A main flow passage 304 is controlled by a
valve 306 which can open to allow flow through the main passage 304
to the valve manifold outlet 302 or close to block such flow. The
second passage is through an orifice 308 in an orifice plate 310
which provides a flow restriction to enhance the ability to
preferentially draw water vapor from the vaporizer/condenser 250. A
third potential passage is through a rupture disk 312 which is
designed to rupture in case of a catastrophic overpressure within
the housing chamber 288, such as in the unlikely event that an
oxidizable sterliant such as hydrogen peroxide combusts therein.
The orifice 308 could be moved to a position within the shut-off
valve 306, similar to that described in reference to the valve
element 118 in FIGS. 3A and 3B.
[0078] In operation, the main chamber is first evacuated to a low
pressure sufficient to induce vaporization, such as 0.4 torr and
the valve 306 is closed placing the vaporizer/condenser 250 into
fluid communication with the chamber 200 solely through the orifice
308. The inlet manifold 252 is heated with the heater 260 and a
quantity of sterliant solution such as a 59% hydrogen
peroxide/water solution is injected into the inlet manifold 252
where it vaporizes and diffuses into the housing 264 through the
apertures 286 and 284. The thermo-electric devices 270 and 272 at
this time are drawing energy out of the rods 278 and dissipating it
through the heat sinks 298 thus allowing the vaporized sterliant to
recondense on the rods 278.
[0079] The temperature of the inlet manifold 252 can be controlled
to slowly vaporize the sterilant thus allowing the water to more
quickly vaporize and flow through the vaporizer 250 and out through
the orifice 308 to concentrate the remaining sterilant. The
condenser/revaporization section 254 quite effectively concentrates
the sterilant such that to speed up the process a fast vaporization
in the inlet manifold can be employed while still achieving a high
degree of concentration.
[0080] The condensate on the rods 278 tends to be more highly
concentrated in the sterilant. After a time, when the initial
charge of sterilant solution has been vaporized and a portion
thereof condensed on to the rods 278, the thermo-electric devices
270 and 272 are reversed to apply heat to the rods 278 and
revaporize the sterilant. At this time, the heat sink 298 will
still contain heat which had been extracted during the prior step
and that heat can be used by the thermo-electric devices 270 and
272 to very efficiently heat the rods 278 and revaporize the
sterilant. This added efficiency improves the energy efficiently of
the device and allows a smaller and more compact vaporize condenser
250 to provide adequate heating and cooling. After the sterilant
has been revaporized, the valve 306 is opened to allow efficient
diffusion of the sterilant vapor into the main chamber 200.
[0081] If a second vaporizer/condenser 216 is employed, its
structure preferably mimics that of the vaporizer/condenser 250
without the inlet manifold 252. In such a system, after initial
diffusion into the main chamber 200, rods within the second
condenser 216 would be chilled and the pump 214 turned on to
preferably extract water vapor from the condensing sterilant. After
a period of time when sterilant has condensed, the rods would be
heated to revaporize the sterilant and the pump 214 turned off.
This revaporized sterilant would have somewhat higher concentration
and would then re-diffuse into the chamber 200 to further enhance
the sterilization process.
[0082] Other system arrangements are possible. FIG. 16 illustrates
an alternative embodiment which can enhance efficiency in
conserving and concentrating the germicide solution. In this
system, a chamber 314 containing a load 316 has a first
condenser/vaporizer 318 connected to a source 320 of germicide
solution and a second condenser/vaporizer 322. The first condenser
vaporizer 318 is isolated from the source 320 by a valve 323 and
from the chamber 314 by a valve 324. It also connects to an exhaust
pump 325 and is isolated therefrom via a valve 326. The second
condenser vaporizer 322 is isolated from the chamber 314 by a valve
327 and connects to the pump 325 and is isolated therefrom via a
valve 328. A vent 329 is also provided.
[0083] FIG. 17 illustrates a similar system 330 employing a single
condenser/vaporizer 332 (of structure similar to the
condenser/vaporizer 250 with an additional outlet) connected to a
sterilization chamber 334 adapted to receive a load 336 of
instruments to be sterilized. A vacuum pump 338 connects to the
chamber 334 via a valve 340 and to the condenser/vaporizer 332 via
a valve 342. A three-way valve may substitute for valves 340 and
342. A source of germicidal solution 344 connects to the
condenser/vaporizer 332 and the chamber 334 has a vent 346. During
initial vaporization and concentration of germicide from the source
344, valve 342 is closed. After the vapor is diffused into the
chamber 334, valve 340 can be closed and the pump 338 used to draw
vapor out of the chamber through the condenser/vaporizer 332 in its
condensing mode to further concentrate the germicide. The
concentrated germicide is then revaporized and diffused back into
the chamber 334.
[0084] The second condenser/vaporizer 216 of FIG. 9 can be used to
maximize germicide utilization when running a sterilization process
with two full cycles of vacuum, inject, diffuse and vent. Prior to
venting during the first cycle, the pump 214 is run with the
condenser/vaporizer 216 being chilled to condense the germicide
therein. The valves 220 and 218 are closed during the venting
process. During the subsequent pump down, the condenser/vaporizer
is kept chilled to keep the germicide from unduly vaporizing and
being carried out of the system.
[0085] The systems of FIGS. 16 and 17 allow even more of the
germicide to be retained between cycles in a two cycle process.
Prior to venting in the first cycle germicide is condensed into the
condenser/vaporizer 332. However, during the subsequent pump down
it can be isolated from the pump via the valve 342 thus minimizing
the tendency of the pump 338 to pump the saved germicide out of the
system during pump down.
[0086] In each of this type of system the steps of condensing and
concentrating the vaporized germicide and then revaporizing it can
be repeated as needed to further concentrate the germicide.
[0087] FIG. 18 illustrates a system 350 plumbed in an alternative
fashion. In this system 350 a condenser/vaporizer 352 connects
through a valve 354 to a sterilization chamber 356 adapted to
receive a load 358 and having a vent 360. A vacuum pump 362
connects to the condenser/vaporizer 352 through a valve 364, but
has no separate connection to the chamber 356. A source 366 of
germicide connects to the condenser/vaporizer 352.
[0088] FIG. 19 illustrates a system 370 plumbed as in FIG. 17,
having a condenser/vaporizer 372 which connects through a valve 374
to a sterilization chamber 376 adapted to receive a load 378 and
having a vent 380. A vacuum pump 382 connects to the
condenser/vaporizer 372 through a valve 384, but has no separate
connection to the chamber 356. Rather than an inlet for germicide
through the condenser/vaporizer 382, a source 386 of germicide
solution is provided within the chamber 376. The source can be
simple such as a well containing a quantity of liquid germicide
solution. Preferably, it is covered with a semi-permeable membrane
or filter so that liquid germicide can not be accidentally spilled
therefrom yet as the germicide vaporizes under low chamber
pressures the vapors thus generated can pass through the membrane
into the chamber. In both systems the condenser/vaporizer 352 or
372 concentrates the germicide via condensation and revaporization
of germicide vapor as described above.
[0089] FIG. 20 illustrates a further embodiment of an inlet
condenser/vaporizer 400. It is similar in most respects to that
illustrated in FIG. 12. However, as shown primarily in FIGS. 21 and
22, it features an orifice control valve 402. A valve block 404
receives an outlet control valve 406, a rupture disk 408 and the
orifice control valve 404.
[0090] FIG. 21 shows the valve block 404 in isolation and
illustrates three manifold passages which connect the valve block
404 to the rest of the condenser/vaporizer 400: a large pressure
relief manifold passage 410 which leads to the rupture disk 408, a
smaller upper manifold passage 412 which leads to the outlet
control valve 406 and a smaller lateral manifold passage 414 which
leads to an orifice 416 and the orifice control valve 402.
[0091] FIG. 22 best illustrates the orifice control valve 402. A
valve seat 418 on the valve block 404 surrounds the orifice 416. A
valve member 420 on the orifice control valve 402 can extend toward
to valve seat 418 to seal against it and block fluid communication
through the orifice 416. A cleaning pin 422 penetrates the orifice
416 when the orifice control valve 402 is closed to clean the
orifice 416 and keep it clear of foreign matter. An annular guide
424 connected to the valve member 420 slides within a bore 426
within the valve block 404 to properly align the cleaning pin 422
with the orifice 416. This view also illustrates a valve seat 428
for the outlet control valve 406 and a valve block outlet passage
430 which leads to the sterilization chamber (not shown in FIGS. 20
to 22).
[0092] Operation of a sterilization cycle proceeds nearly the same
as afore-described regarding the system shown in FIGS. 12 to 15.
However, after the initial vaporization of the sterilant in the
inlet manifold 252 (see FIG. 14) the orifice control valve 402 is
closed thereby isolating the condenser/vaporizer 400 from the
sterilization chamber (not shown in FIGS. 20 to 22). This condition
can be monitored most easily be monitoring the pressure within the
vaporizer/condenser 400 and assuming that when a particular
pressure has been reached that essentially all of the sterilant has
been vaporized. Pressure in the sterilization chamber is then
reduced, preferably to approximately 0.5 Torr. The outlet control
valve 406 is then opened and the rods 278 (see FIG. 14) are heated
to vaporize condensed sterilant and pass it through the outlet
control valve 406 and outlet passage 430 to the sterilization
chamber.
[0093] By lowering the pressure in the sterilization chamber prior
to admitting the bulk of the sterilant it has been found that
overall cycle times may be reduced. Closing the orifice control
valve 402 and reducing pressure in the sterilization chamber takes
additional time. However, the lower pressure provides a more
favorable condition for diffusion of the sterilant into diffusion
restricted areas, such as lumens, of instruments to be sterilized.
It has been found that the time saved through the increased
diffusion efficiency can more than offset the time lost in lowering
the pressure in the sterilization chamber. Sterilization cycle
speed is an important factor for sterilizer users.
[0094] Water vapor in the sterilization chamber can affect the time
required to lower the pressure therein. Such water vapor typically
arises from a load of instruments that have not been properly
dried. If undue time is required to remove the water vapor it can
be indicated to the user so that they can be reminded to be more
vigilant in drying the load for future cycles. There may exists
loads of water vapor for which it may take too long to withdraw or
to withdraw effectively. In such case the cycle should be cancelled
and the user informed as to why.
[0095] Table 2 shows control points for three different cycles--a
flash or very quick cycle having no lumens, a short cycle having
only lumens which present a mild challenge and a long cycle for
sterilizing devices with more challenging long and narrow lumens.
During an initial pump-down to remove air from the sterilization
chamber and vaporizer/condenser 400 the outlet control valve 406 is
left open. As the pressure reaches P1 the outlet control valve 406
is closed but the orifice control valve 402 is left open; this
starts the vaporization and concentration of the sterilant. Upon
reaching pressure P2 within the vaporizer/condenser 400 the
pressure Pc within the chamber is checked. If it is above the value
listed in Table 2 then the orifice control valve 402 is closed and
pump-down continues until Pc is reached and then the outlet control
valve 406 is opened to transfer the sterilant into the
sterilization chamber. Otherwise, the outlet control valve 406 is
opened right away. If the chamber pressure exceeds Pc-cancel at the
time that the vaporizer/condenser pressure reaches P2 it is assumed
that the sterilization chamber contains too much water and the
cycle is cancelled. TABLE-US-00002 TABLE 2 Examples of temperature
and pressure set points Short Long Flash 1 mm .times. 150 mm SS 1
mm .times. 500 mm SS Load condition Surface 1 mm .times. 350 mm
Plastic 1 mm .times. 1000 mm Plastic Vaporizer temperature
70.degree. C. 70.degree. C. 70.degree. C. Condenser temperature
58.degree. C. 52.degree. C. 43.degree. C. P1 Vaporizer/condenser
140 torr 140 torr 140 torr pressure to remove air P2
Vaporizer/condenser 22 torr 16 torr 10 torr pressure to concentrate
sterilant Pc Chamber pressure to 1.5 torr 0.6 torr 0.3 torr select
transfer, additional vacuum or cancellation Pc-cancel Chamber 8
torr 6 torr 4 torr pressure to cancel cycle Condenser temperature
68.degree. C. 68.degree. C. 68.degree. C. to transfer concentrated
sterilant
[0096] The invention has been described with reference to the
preferred embodiments. Obviously, modifications and alterations
will occur to others upon reading and understanding the preceding
detailed description. It is intended that the invention be
construed as including all such modifications and alterations
insofar as they come within the scope of the appended claims or the
equivalents thereof.
* * * * *